ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the mechanism by which
methodsAn optimized co-culture model of RA-derived fibroblast-like synoviocytes (RA-FLS) and human umbilical vein endothelial cells (HUVECs) was treated with gradient concentrations of HQC-medicated serum with or without plasmid transfection for LncRNA EBLN3P overexpression. The inhibitory effects of HQC on pathological behaviors of RA-FLS were assessed using EdU assay, Transwell invasion assay, and scratch wound healing assay. Cellular secretions of pro-angiogenic factors (VEGF and FGF2) and matrix metalloproteinases (MMP2 and MMP9) were measured by ELISA. HUVEC tube formation capacity and expressions of the endothelial markers CD34 and CD105 were evaluated, and the expressions of molecules in the LncEBLN3P/miR-369-3p/NFIX axis and the JAK2/STAT3 pathway were detected using qRT-PCR and Western blotting.
resultsThe RA-FLS exhibited significantly enhanced proliferation, invasion, and migration with upregulated expressions of VEGF, FGF2, MMP2, and MMP9 and dysregulation of tthe LncEBLN3P/miR-369-3p/NFIX axis, as shown by decreased miR-369-3p and increased expressions of LncEBLN3P, NFIX, JAK2, STAT3, p-JAK2, and p-STAT3. Treatment with HQC-medicated serum effectively reversed these pathological changes, suppressed malignant phenotype of the cells, downregulated angiogenic and matrix-degrading factors, and inhibited the axis and pathway activity. In the LncRNA EBLN3P overexpression (OE-Lnc) model, HQC treatment less effectively reversed the pathological phenotype and pathway activation in the cells as compared to its effect in the non-overexpression setting.
conclusionsHQC inhibits pro-angiogenic function of RA-FLS likely by targeting the LncRNA EBLN3P/miR-369-3p/NFIX axis, thereby suppressing the downstream JAK/STAT signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.